Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02157519 · ClinicalTrials.gov registry record · NA
Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 212
- Enrollment target
NCT02157519: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02157519 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 212 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02157519, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 212 participants
- Enrollment target
Study Summary
Many people treated for cancer receive oral chemotherapy medications for their illness. This means that much of their cancer care occurs at home, away from a traditional oncology care setting. The purpose of this study is to explore how a Smartphone mobile application ("mobile app") can help improve the cancer treatment process in people who are prescribed oral chemotherapy medication. The investigators will explore how well the mobile app helps patients stay connected with their oncology care team, take their oral medications as prescribed, and manage their cancer-related symptoms from home. This study will be done in two phases: 1) a pilot phase to assess the feasibility of a mobile application intervention, and 2) a randomized-controlled trial to test the intervention.
Primary Outcome
The Morisky Medication Adherence Questionnaire (MMAS-4) - a 4-item questionnaire that assesses medication adherence in the past week by asking patients to indicate "yes" or "no" to each item (self-report). The four items ask patients to self-report whether they forgot to take their oral chemotherapy (OC) medication in the past week, whether they had any problems remembering to take their OC medication in the last week, whether they stopped taking their OC medication when they felt better in the
Interventions
- OTHER Mobile Application Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2015-02-18 |
| Est. Completion | 2016-12-31 |
| Phase | NA |
What the finished NCT02157519 record still lists
NCT02157519 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Mobile Application Intervention is the first listed.
NCT02157519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02157519 about?
NCT02157519 is a clinical study titled "Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer". Many people treated for cancer receive oral chemotherapy medications for their illness. This means that much of their cancer care occurs at home, away from a traditional oncology care setting. The purpose of this study is to explore how a Smartphone mobile application ("mobile app") can help improve...
What is the current status of trial NCT02157519?
This trial is currently completed. It is a NA study. The enrollment target is 212 participants. The study started on 2015-02-18. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT02157519?
The interventions under investigation include: Mobile Application Intervention (OTHER).
Who is sponsoring clinical trial NCT02157519?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02157519's enrollment target sits among peer trials
212 489th of 2000 higher than 1,511 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI